GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Piotroski F-Score

PODD (Insulet) Piotroski F-Score : 8 (As of Jul. 04, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Insulet Piotroski F-Score?

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Insulet has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Insulet's Piotroski F-Score or its related term are showing as below:

PODD' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of Insulet was 9. The lowest was 2. And the median was 5.


Insulet Piotroski F-Score Historical Data

The historical data trend for Insulet's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Piotroski F-Score Chart

Insulet Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 4.00 5.00 6.00 9.00

Insulet Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 7.00 9.00 8.00

Competitive Comparison of Insulet's Piotroski F-Score

For the Medical Devices subindustry, Insulet's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Insulet's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was 188.6 + 77.5 + 100.7 + 35.4 = $402 Mil.
Cash Flow from Operations was 96.5 + 98.5 + 147.7 + 63.8 = $407 Mil.
Revenue was 488.5 + 543.9 + 597.5 + 569 = $2,199 Mil.
Gross Profit was 330.9 + 377.1 + 430.9 + 409 = $1,548 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was
(2624 + 2881.6 + 3025.4 + 3087.7 + 3517.3) / 5 = $3027.2 Mil.
Total Assets at the begining of this year (Mar24) was $2,624 Mil.
Long-Term Debt & Capital Lease Obligation was $1,612 Mil.
Total Current Assets was $2,328 Mil.
Total Current Liabilities was $520 Mil.
Net Income was 27.3 + 51.9 + 103.3 + 51.5 = $234 Mil.

Revenue was 396.5 + 432.7 + 509.8 + 441.7 = $1,781 Mil.
Gross Profit was 264.9 + 293.3 + 361.2 + 306.8 = $1,226 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was
(2289.1 + 2385.8 + 2467.7 + 2588.2 + 2624) / 5 = $2470.96 Mil.
Total Assets at the begining of last year (Mar23) was $2,289 Mil.
Long-Term Debt & Capital Lease Obligation was $1,363 Mil.
Total Current Assets was $1,618 Mil.
Total Current Liabilities was $432 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Insulet's current Net Income (TTM) was 402. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Insulet's current Cash Flow from Operations (TTM) was 407. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=402.2/2624
=0.15327744

ROA (Last Year)=Net Income/Total Assets (Mar23)
=234/2289.1
=0.10222358

Insulet's return on assets of this year was 0.15327744. Insulet's return on assets of last year was 0.10222358. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Insulet's current Net Income (TTM) was 402. Insulet's current Cash Flow from Operations (TTM) was 407. ==> 407 > 402 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1612.3/3027.2
=0.53260439

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=1362.6/2470.96
=0.55144559

Insulet's gearing of this year was 0.53260439. Insulet's gearing of last year was 0.55144559. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=2328.4/520.4
=4.47425058

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=1618.4/432.4
=3.74283071

Insulet's current ratio of this year was 4.47425058. Insulet's current ratio of last year was 3.74283071. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Insulet's number of shares in issue this year was 74.111. Insulet's number of shares in issue last year was 73.741. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1547.9/2198.9
=0.70394288

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1226.2/1780.7
=0.6886056

Insulet's gross margin of this year was 0.70394288. Insulet's gross margin of last year was 0.6886056. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=2198.9/2624
=0.83799543

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=1780.7/2289.1
=0.77790398

Insulet's asset turnover of this year was 0.83799543. Insulet's asset turnover of last year was 0.77790398. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Insulet has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Insulet  (NAS:PODD) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Insulet Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Insulet's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Executives
John W. Kapples officer: SVP, Secretary and GC C/O GCP APPLIED TECHNOLOGIES INC., 62 WHITTEMORE AVENUE, CAMBRIDGE MA 02140
Eric Benjamin officer: SVP, R&D, New Prod Dev. & Comm C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DR, SUITE 200, BILLERICA MA 01821
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202
Lauren Budden officer: VP, CAO and Controller C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720